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Vascular endothelial growth factor (VEGF) could play a
relevant role in angiogenesis associated with chronic
allograft nephropathy. Interleukin-1b (IL-1b) has a key role
in inflammatory response. It induces prostaglandin (PG) E2,
which is involved in VEGF release by some normal and tumor
cells. In the present work, we studied the effect of IL-1b on
VEGF release by rat mesangial cells, the transduction signal,
and whether or not PGE2 is involved in this effect. IL-1b
induced a time-dependent formation of VEGF (analyzed by
enzyme-linked immunosorbent assay) and PGE2 (analyzed
by enzyme immunoassay). The latter correlated with
microsomal-PGE-synthase (mPGES)-1 expression rather than
with cyclooxygenase (COX)-2 in terms of protein, determined
by Western blotting. No effect of IL-1b on COX-1, cytosolic
PGES, or mPGES-2 expression was observed. Indomethacin
exerted a nonsignificant effect on IL-1b-induced VEGF,
and exogenously added PGE2 exhibited a nonsignificant
stimulatory effect on VEGF formation. SB 203580, a p38
mitogen-activated protein kinase inhibitor, weakly inhibited
the induction of VEGF by IL-1b in a concentration-dependent
manner, whereas LY 294002, a phosphoinoside 3-kinase
(PI3-K) inhibitor, and rapamycin, a mammalian target of
rapamycin (mTOR) inhibitor, strongly inhibited both
IL-1b- and tumor necrosis factor-a-induced VEGF formation
in a concentration-dependent manner. Rapamycin also
decreased glomerular VEGF levels in the anti-Thy1.1
model of experimental glomerulonephritis. In conclusion,
the PI3-K-mTOR pathway seems to be essential in
cytokine-induced release of VEGF in mesangial cells.
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Although immunosuppression has improved considerably
over the last 10 years, chronic allograft nephropathy (CAN) is
still a major cause of late graft failure.1 This slowly
progressing allograft nephropathy is characterized by vascular
obliteration owing to proliferation and scarring of intima and
media in renal vessels, and membrane multilayering in the
peritubular capillaries. The interstitium also shows gradual
fibrosis and generation of extracellular matrix. Tubules
develop atrophic features.2 Chronic inflammation is accepted
to be the driving process of CAN. Inflammation mediators
such as inflammatory cells, cytokines, growth factors, and
vasoactive agents including eicosanoids can be found at
different stages of progressive CAN. Inflammatory angio-
genesis could be involved in chronic endothelial activation
leading to arteriosclerosis-like CAN. Infiltration of leukocytes
seems to be essential for CAN development.3 Angiogenesis
has been shown to facilitate leukocyte recruitment through
its interaction with microvascular endothelium.3 Leukocyte
activation and neovascularization form a vicious circle that
results in high levels of cytokines and other inflammatory
mediators that potentially promote interstitial fibrosis.
Interleukin-1 (IL-1) is a primary inflammatory cytokine
produced by a variety of cells such as monocytes/macro-
phages and endothelial cells, which play a fundamental role
in orchestrating the inflammatory response.4 IL-1 has been
found to be a pro-angiogenic factor that promotes tumor
progression5–8 and induces vascular endothelial growth factor
(VEGF) in several cell types.9–11 Although several molecules
have been shown to be important in angiogenesis, VEGF
stands out because it is a direct specific mitogen for
endothelial cells and appears to function as a key regulator
of physiologic as well as pathologic angiogenesis.12 In
humans, VEGF has been reported to be induced in
association with chronic interstitial inflammation in renal
allografts with evidence of CAN.13
IL-1 can exert its biological effect in part by induction of
prostanoid generation.10,14,15 Indeed, prostaglandin (PG) E2
is involved in neovascularization16,17 and induces endo-
thelial-targeted growth factors.18,19 VEGF expression is
regulated by the transcription factor hypoxia-inducible
factor-1 (HIF-1).20 HIF-1 regulates a number of genes,
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globally leading to cell adaptation to a lack of oxygen and
orchestrating the neovascularization process by promoting
expression of matrix metalloproteinases (MMPs), adhesion
molecules, and chemokines.21 It has been reported that PGE2
induces not only stabilization of HIF-1a,22 the oxygen-
regulated subunit of HIF-1, but also HIF-1a protein
synthesis.23
PGH2, formed from arachidonic acid by the catalytic
action of cyclooxygenase (COX), is the common intermediate
in the biosynthesis of the two series of prostanoids, including
PGE2. Three isoforms of COX have been fully characterized
to date. Two of these are encoded by the COX-1-gen (COX-1
and COX-3) and COX-2 is encoded by a separate gene. In
general, COX-1 can be viewed as a constitutive enzyme
and prostanoids formed through the action of COX-1 (also
COX-3) mediate so-called ‘housekeeping’ functions,
such as the regulation of renal function, maintenance of
the gastric mucosa integrity, and hemostasis. In contrast,
COX-2 is an inducible enzyme, which is normally expressed
in few tissues and cell types including renal macula densa, but
is expressed transiently in response to hormones, growth
factors, pro-inflammatory cytokines, bacterial endotoxins,
and tumor promoters. COX-2 is typically induced at the
inflammatory sites (reviewed by Vila24). COX-2 induction
results in an increase in PGE2 production, and in some
cell types, such as endothelial and mesangial cells, it also
results in the release of untransformed PGH2,
25–27 which is a
potent vasoconstricting agent. The enzymes that catalyze
conversion of PGH2 to PGE2 are known as PGE-synthases
(PGES). The first to be identified and characterized was a
16 kDa protein (PIG12, MGST1-L1), which is a member of
the MAPEG (Membrane-Associated Proteins involved in
Eicosanoid and Glutathione metabolism) superfamily with
glutathione-dependent PGES activity.28 This enzyme, now
called microsomal-PGE-synthase (mPGES)-1, is located in
chromosome 9 and is inducible by pro-inflammatory
cytokines. mPGES-1 is induced by IL-1b and tumor necrosis
factor-a (TNFa).26,28 Moreover, functional coupling of
mPGES-1 with COX-2 has been reported.29 The tandem
COX-2/mPGES-1 appears to be responsible for the inflam-
matory production of PGE2. Conversely, a cytosolic PGES
(cPGES) seems to act coupled with COX-1.30 cPGES is
ubiquitously expressed and identical to p23, a protein
somehow related with steroid hormone receptor-mediated
signal transduction. Another type of mPGES, known as
mPGES-2, has been considered to use substrate coming from
both COX-1 and COX-2 activities.31
It has been reported that mesangial cells can release
VEGF32 and promote capillary formation in vitro.5 On the
other hand, COX-2-derived PGE2 appears to be essential
for inflammatory cytokine-induced angiogenesis.14,33 IL-1
induces COX-2-mediated production of PGE2 formation
in mesangial cells.27 Hence, the present work was conducted
to study the effect of IL-1 on the expression of VEGF
in mesangial cells, and to determine whether or not PGE2
biosynthetic machinery is involved in this effect.
RESULTS
Figure 1a shows the effect of IL-1b on VEGF-release by rat
glomeruli mesangial cells (RGMCs) as a function of time. IL-
1b significantly induced VEGF in a time-dependent manner.
This effect was not only observed in terms of protein but also
in terms of mRNA (Figure 1b). IL-1b also significantly
induced PGE2 formation with a time-course pattern similar
to that of VEGF (Figure 2a). The time course of COX-2
expression (Figure 2b and c) indicated that IL-1b time
dependently induced COX-2 with a pattern shifted to the left
respect to that of PGE2. Downstream enzymes in the PGE2
biosynthetic pathway were also studied. Figure 2c shows a
representative Western-blotting analysis of mPGES-1,
mPGES-2, and cPGES. RGMC expressed all three PGES
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Figure 1 | Time course of IL-1b-stimulated expression of VEGF by
RGMC. Cells were incubated with 100 U/ml of human recombinant
IL-1b. After the indicated periods of time, (a) VEGF levels in
the culture medium were determined by enzyme-linked
immunosorbent assay; (b) mRNA was determined by real-time
reverse transcriptase-polymerase chain reaction. N¼ 4, mean7s.e.m.,
*Po0.05, when compared with controls.
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Figure 2 | Time course of PGE2 release, and COX-2 and mPGES-1
expression in response to IL-1b. Time course of (a) IL-1b-stimulated
release of PGE2 and (b and c) enzyme expression in RGMC. RGMC
were incubated with 100 U/ml IL-1b for the indicated periods of time.
PGE2 levels were then evaluated. N¼ 4, mean7s.e.m., *Po0.05,
**Po0.01 when compared with controls. Protein expression was
analyzed by Western blotting. (b) Density was normalized to the
most dense band; n¼ 4, mean7s.e.m. (c) Representative gels from
four independent analysis are also shown.
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isozymes, although mPGES-1 was the only enzyme induced
by IL-1b in a time-dependent manner. The time-course
pattern of mPGES-1 was shifted to the right respect to that of
COX-2. Moreover, the PGE2 time-course curve matched that
of mPGES-1 better than that of COX-2. Of note, despite the
fact that RGMC expressed mPGES-2 and cPGES, production
of PGE2 was very low in IL-1b-untreated cells and only when
COX-2 and mPGES-1 were induced PGE2 was produced in
considerable amounts.
Despite the fact that IL-1b-induced expression of PGE2
biosynthetic machinery, results in Figure 3 show that
10 mmol/l indomethacin, which inhibited PGE2 formation
more than 90%, did not modify IL-1b-induced VEGF release
by RGMC. In addition, incubation of IL-1b-untreated cells
with 0.1 and 1 mmol/l of purified PGE2 did not modify VEGF
release (Figure 3). Nevertheless, 1 mmol/l of purified PGE2
significantly induced MMP-2 expression in terms of mRNA
(2DCt : 7.3 10371.7 103 and 20.9 10374.3 103;
mean7s.e.m., n¼ 4 for control and PGE2-treated cells,
respectively). In our cells, we observed EP-1, EP-3, and EP-
4 expression in terms of mRNA with an almost undetectable
expression of EP-2 (2DCt : 0.37 10470.09 104 for
EP-1, 2.43 10471.55 104 for EP-3, and 2.04
10470.69 104 for EP-4; mean7s.e.m., n¼ 6 different
cell lines in independent experiments; EP-2 was not amplified
except in one cell line, 2DCt : 0.29 104).
To explore the signaling pathways involved in IL-1b-
induced VEGF expression, RGMCs were incubated with
IL-1b plus a fixed concentration (see Materials and Methods
section) of several kinase inhibitors in the presence of
indomethacin to guarantee an effect independent of PGE2.
Three separate experiments were performed. A high con-
centration of the general protein kinase C (PKC) inhibitor GF
109203X did not inhibit the effect of IL-1b on VEGF
production. Nor did the Ca2þ -dependent PKC inhibitor, Go¨
6976. Moreover, 10 nmol/l phorbol-12-myristate-13-acetate
was unable to induce VEGF, whereas it clearly induced COX-
2. The MAPK/Extracellular signal-regulated Kinases 1 and 2
(MEK 1/2) inhibitor U0126 did not significantly modify IL-
1b-induced production of VEGF (results not shown). Only
three of the signaling inhibitors tested significantly inhibited
IL-1b-induced release of VEGF. These inhibitors were then
assayed again to study their concentration-dependent effect.
Figure 4a shows the effect of SB203580 (a p38 mitogen-
activated protein kinase (p38-MAPK) inhibitor), rapamycin
(a mammalian target of rapamycin (mTOR) inhibitor), and
LY-294002 (phosphoinoside 3-kinase (PI3-K) inhibitor),
on IL-1b-induced release of VEGF. All three inhibited the
IL-1b-induced release of VEGF in a concentration-dependent
manner. LY-294002 and rapamycin were able to suppress the
effect of IL-1b on VEGF release by more than 80%. The p38-
MAPK inhibitor, SB203580, exerted a maximum inhibition
of about 40%, at the highest concentration. When 0.1 mmol/l
rapamycin and 10 mmol/l SB203580 were used together, a
total suppression of IL-1b-induced VEGF was observed. To
verify if these pathways were also involved in VEGF
expression induced by other cytokines, RGMC were treated
with TNFa for 24 h and subjected to the same studies as IL-
1b-treated cells. TNFa also significantly induced VEGF
formation by RGMC in terms of protein (data not shown).
The inhibition pattern of VEGF induction was similar to that
of IL-1b, with SB203580, rapamycin, and LY-294002 being
the only active inhibitors. Figure 4b shows the concentration-
dependent effect of these compounds on TNFa-induced
VEGF that was similar to, or even more potent than that on
IL-1b-induced VEGF.
To observe the effect of mTOR inhibition on VEGF levels
in vivo, the anti-Thy1.1 model of experimental glomerulone-
phritis was used. Figure 5 shows immunoblotting analysis of
VEGF in glomeruli of untreated- and rapamycin-treated rats.
Results showed a clear reduction on VEGF levels in gomeruli
from rapamycin-treated rats. Values of densitometric analysis
are shown in the legend of Figure 5.
DISCUSSION
IL-1 appears to be required for both angiogenesis and tumor
invasiveness in IL-1-knockout mice.6 Several studies have
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Figure 3 | Effect of indomethacin and exogenous PGE2 on VEGF
release by RGMC. Cells were treated for 24 h with 100 U/ml IL-1b
in the presence (IL-1Bþ Indo) or absence (IL-1B) of 10 mmol/l
indomethacin; n¼ 4; mean7s.e.m. To evaluate the effect of
exogenous PGE2 on VEGF release, cells were pre-incubated for 10 min
with 10 mmol/l indomethacin and then incubated with 0 (control), 0.1
and 1 mmol/l of purified PGE2 for 24 h. VEGF levels were then
evaluated; n¼ 6; mean7s.e.m.
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Figure 4 | Effect of PI3-K, mTOR, and p38-MAPK inhibitors on
IL-1b-induced VEGF. Cells were treated with (a) 100 U/ml IL-1b or
(b) 20 ng/ml TNFa plus 10mmol/l indomethacin for 24 h in the presence
or absence of the indicated concentrations of rapamycin (mTOR
inhibitor) or LY 294002 (PI3-K inhibitor) and SB 203580 (p38-MAPK
inhibitor). VEGF levels were then determined; n¼ 4; mean7s.e.m.
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reported that IL-1 promotes tumor growth, invasion, and
angiogenesis in animal models with concomitantly enhanced
production of VEGF, MMPs, chemokines, and adhesion
molecules.7,8 IL-1 also promotes angiogenesis in vivo through
the VEGF receptor pathway, possibly by inducing VEGF
synthesis.34 Mesangial cells are reportedly able to release
VEGF32 and this factor is determinant for mesangial cell-
induced capillary formation in vitro.5 The present data show
that IL-1b substantially increases VEGF expression in terms
of both protein and mRNA, by RGMC, indicating an action
at the transcriptional level.
Based on previous reports concerning various cell
types,10,14,15 our initial focus was mainly driven by the
assumption that PGE2 partially mediates the possible effect of
IL-1b. We therefore analyzed the PGE2 production and the
biosynthetic pathway involved. In a previous report, we
postulated that resting RGMC did not produce PGE2
enzymatically, whereas in IL-1b-treated cells PGE2 was
produced by enzymatic catalysis.27 Nevertheless, enzymes
involved in the transformation on PGH2 to PGE2 were not
characterized at that time. In the present study, we show that
RGMC constitutively express cPGES and mPGES-2. We also
observed that these isozymes were not induced by IL-1b,
which is consistent with other reports.30,31 Arachidonic acid
mobilization is the first step in prostanoid biosynthesis.
Hence, phospholipase activation is required for prostanoid
synthesis from endogenous substrate. The fact that resting
RGMC did not produce substantial PGE2 could be due to low
phospholipase activity, which results in a low COX substrate
availability. However, we previously observed that PGE2
formation by RGMC from exogenously added substrate
was mainly non-enzymatic.27 Moreover, specific PGES
activity, incubating RGMC with exogenous purified PGH2,
was only detected in IL-1b-treated cells (data not shown).
Taking our previous data into account, these present results
indicate that cPGES and mPGES-2 are not relevant for PGE2
biosynthesis in RGMC. In contrast, mPGES-1 was not
detectable in resting RGMC, and production of PGE2 from
endogenous substrate was only relevant when IL-1b induced
its expression. This indicates that mPGES-1 was the
main PGES isozyme responsible for PGH2 conversion to
PGE2 in RGMC.
Despite the fact that IL-1b significantly increased the
ability of RGMC to synthesize PGE2, indomethacin, a strong
inhibitor of both COX-1 and COX-2, was unable to alter
IL-1b-induced VEGF production. In addition, exogenously
added PGE2 was also unable to modify VEGF production in
resting cells, whereas consistently with previous reports it
increased MMP-2.35 All together, these results allow us to rule
out the idea that PGE2 mediates in the effect of IL-1b on
VEGF in RGMC. Cell-type-specific regulation of VEGF
expression by PGE2 could be related to the presence of the
different PGE2 receptor subtypes. In agreement with others,
36
we observed expression of EP-1, EP-3, and EP-4, whereas
EP-2 was not usually amplified by reverse transcriptase-
polymerase chain reaction. One possibility is that the
engagement of different PGE2 receptors could have opposing
actions37 and these could lead to a weak net effect. More
research is required to explore this possibility in the case of
PGE2 modulation of VEGF expression in RGMC.
Engagement of IL-1b receptors triggers off several
signaling pathways in mesangial cells. A prominent signaling
pathway that mediates the response to IL-1 is that of the
MAPKs. Members of this family include cJun N-terminal
kinases, p38-MAPK, and extracellular signal-regulated ki-
nases. IL-1b can activate all three subgroups of MAPKs in
renal mesangial cells.38 Another kinase which is activated in
response to various extracellular signals, including growth
factors, insulin, and insulin-like growth factors, is PI3-K.
IL-1b activates this pathway in some cell types.39 PKCs are
involved in VEGF induction by mechanical stress in
mesangial cells.40 PKCs are also involved in several IL-1b
responses.41,42 The biological outcome of the activation of
these pathways and the pathways involved in the induction of
a particular gene expression is cell-type-dependent. We tested
different inhibitors of the aforementioned pathways to
explore signaling involved in VEGF induction by IL-1b in
RGMC.
According to their structure and cofactor requirements
PKC isoforms have been classified into: conventional PKCs
(Ca2þ and diacyl-glycerol-dependent), novel PKCs (diacyl-
glycerol -dependent and Ca2þ independent), and atypical
PKCs (Ca2þ independent and not activated by phorbol
esters).43 High concentrations of the general PKC inhibitor
GF 109203X did not inhibit the effect of IL-1b on VEGF
production. Nor did the Ca2þ -dependent PKC inhibitor, Go¨
6976, inhibit the IL-1b action. Moreover, 10 nmol/l phorbol-
12-myristate-13-acetate was unable to induce VEGF, whereas
it clearly induced COX-2 (data not shown). All together,
these results indicated that IL-1b did not involve PKCs in
VEGF induction. U0126 inhibits MEK 1/2, a MAPK-kinase
which phosphorylates extracellular signal-regulated kinase 1/
2 in the Raf-extracellular signal-regulated kinase pathway.44
The fact that U0126 did not significantly modify IL-1b-
induced production of VEGF allows us to rule out the idea
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Figure 5 | Effect of rapamycin administration on glomerular
VEGF protein in the anti-thy.1.1 model of glomerulonephritis.
Experimental glomerulonephritis was induced by a single injection
of the monoclonal anti-Thy1.1 (1 mg/1 kg body weight). Placebo
solution or a dose of 3 mg rapamycin/kg body weight/day was
administered intraperitoneally daily from the third day after
antibody administration until the seventh day, when all rats were
killed. Glomeruli were isolated from individual rats, immediately
lysated, and Western blotting for VEGF expression was performed.
b-Actin was detected as loading control. Densitometric evaluation
was 10.3572.09 and 2.3870.29 for untreated and
rapamycin-treated rats, respectively; mean7s.e.m.; relative to
b-actin density in arbitrary units, n¼ 4; Po0.01.
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that the Raf-extracellular signal-regulated kinase pathway is
involved in the action of IL-1b on VEGF in RGMC.
p38-MAPK is a typical MAPK signaling pathway activated
by IL-1.11 The p38-MAPK inhibitor SB203580 partially
inhibited IL-1b-induced VEGF by about 40%, indicating
that this pathway is somehow involved in the action of IL-1b.
Nevertheless, only the PI3-K inhibitor LY 294002 totally
suppressed the action of IL-1b on the VEGF. The atypical
PKC, PKCx, appears to be a downstream effector of PI3-K,45
which is activated by IL-1b in renal mesangial cells.42 The fact
that neither the general PKC inhibitor GF 109203X nor PKCx
pseudosubstrate inhibited the IL-1b-induced VEGF indicated
that PKCx was not involved in the signaling pathway of this
action in RGMC. Another downstream effector of PI3-K is
mTOR, which regulates protein synthesis at a transcriptional
and post-transcriptional level.46,47 The fact that rapamycin
highly inhibited the action of IL-1b on VEGF production
indicates that PI3-K/mTOR pathway is a fundamental
signaling pathway involved in the action of IL-1b. Moreover,
this pathway was also involved in VEGF expression induced
by TNFa, which also plays a pivotal role in the inflammatory
response. These findings have relevance as rapamycin
(sirolimus) is an emerging alternative to calcineurin in-
hibitors in CAN treatment.48 Beside its immunosuppressive
capability, rapamycin bears antitumor properties apparently
based on its capability to inhibit angiogenesis49 and to induce
thrombosis in tumor microvasculature.50
VEGF is the most specific and relevant pro-angiogenic
agent. The present results point out the relevance of renal
mesangial cells as a source of VEGF, particularly when
stimulated with pro-inflammatory cytokines. We show that
the action of IL-1b regarding VEGF formation by RGMC
does not depend on PGE2 formation, despite the fact that
PGE2 biosynthetic machinery is concomitantly induced by
the cytokine. The effect of IL-1b and TNFa on VEGF promo-
tion was highly dependent on the PI3-K/mTOR pathway,
strongly sensitive to rapamycin. In addition, rapamicyn also
decreased VEGF levels in glomeruli in a well-established51
model of mesangial proliferative glomerulonephritis in which
VEGF gene expression is induced.52
Inflammation is the driving process of CAN and VEGF
is a relevant mediator in inflammation. Nevertheless, the
exact role of VEGF in CAN is controversial. Pilmore et al.13
observed that VEGF was increased in CAN, and by
immunohistochemistry analysis it was found in the inter-
stitium and glomeruli associated to macrophages, podocytes,
and mesangial cells, and also in vascular cells. Using
immunohistochemical analysis, a more recent report also
found that VEGF was increased in CAN patients, localized in
the interstitium, tubuli, and glomeruli.53 In this study, 41%
CAN patients showed positivity in mesangium. In contrast,
Hotchkiss et al.54 found that glomerular VEGF was down-
regulated in CAN patients. It is difficult to ascertain the
origin of these discrepancies. In any case, here we
demonstrate that IL-1b strongly induces VEGF expression
in RGMC and this effect, as occurred with the induction by
TNFa and in experimental glumeronephritis, is rapamycin
sensitive. These findings could have relevance in the context
of CAN where rapamycin is a promising therapeutic tool,
despite the fact that rapamycin has been shown to be
associated with increased proteinuria in patients after renal
transplantation with advanced CAN after conversion to
rapamycin.55 In addition, use of rapamycin in human
glomerulonephritis has been shown to be detrimental. More
research is needed to ascertain the exact role of VEGF in CAN
and chronic inflammatory nephropathies, and whether or
not adverse effects of rapamycin are related with its effect on
VEGF induction.
MATERIALS AND METHODS
Mesangial cell culture and treatment
RGMC were isolated, cultured, and characterized as described
previously.27 Cells were used in passages 4–8. They were incubated
with 100 U/ml of human recombinant IL-1b (Roche Applied
Science, Barcelona, Spain) for the indicated (in the Results section)
period of time. The culture medium was removed and stored at
801C until VEGF or PGE2 analysis. Cells were immediately lysated
as described previously56 and stored at 801C until enzyme
expression analysis.
To evaluate the effect of indomethacin on VEGF release, RGMC
were treated with 100 U/ml IL-1b in the presence or absence of
10 mmol/l indomethacin for 24 h. VEGF levels were then evaluated.
To evaluate the effect of exogenous PGE2 on VEGF release, cells
were pre-incubated for 10 min with 10 mmol/l indomethacin and
then incubated with 0, 0.1, and 1 mmol/l of purified PGE2 for 24 h.
VEGF levels were then evaluated.
COX-2, mPGES-1, mPGES-2, and cPGES protein levels
Total protein equivalents of each sample were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membranes (Immobilon-P, Millipore
Ibe´rica, Madrid, Spain). Nonspecific binding of the antibody was
blocked by treating the membrane with 10% w/v non-fat dried milk
in 50 mmol/l Tris-HCl pH 7.4 containing 150 mmol/l NaCl overnight
at 41C. Membranes were then incubated with polyclonal antibodies
for COX-2 (Oxford Biomedical Research Inc, Oxford, MI, USA),
mPGES-1, mPGES-2, or cPGES (all from Cayman Chemical, Ann
Arbor, MI, USA). Enhanced chemiluminesence System (Amersham
Bioscience Biotech Europe GmbH, Barcelona, Spain) was used for
detection, according to the manufacturer’s instructions.
VEGF, PGE receptor (EP-1, EP-2, EP-3, and EP-4), and MMP-2
mRNA analysis
For mRNA expression, cells were treated with IL-1b as aforemen-
tioned, and total RNA was extracted. The mRNA expression was
evaluated by real-time polymerase chain reaction in an ABI Prism
7000 by means of pre-designed validated assays (TaqMan Gene
Expression Assays; Applied Biosystems, Foster City, CA, USA) using
the Comparative Ct method (User bulletin 2, Applied Biosystems).
The amount of RNA was normalized to eucaryotic 18s rRNA as
endogenous control and RNA of untreated cells was used as a
calibrator sample.
Analysis of PGE2 in the conditioned medium
PGE2 was analyzed by specific enzyme immunoassay (Amersham-
Biosciences Europe GmbH) following the manufacturer’s instructions.
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Signaling pathways involved in VEGF expression
In a first approach, RGMC were pre-incubated for 30 min with
10 mmol/l indomethacin. A 100 U/ml portion of IL-1b were then
added, and incubated for 24 h in the absence or presence of 5 mmol/l
GF 109203X (a general PKC inhibitor, Sigma-Aldrich Quı´mica SA,
Madrid, Spain), 10mmol/l SB203580 (a p38-MAPK inhibitor,
Sigma), 10 mmol/l U0126 (a MEK 1/2 inhibitor, Sigma), 0.1 mmol/l
rapamycin (a mTOR inhibitor, Sigma), 10 mmol/l LY-294002 (a PI3-
K inhibitor, Calbiochem, Darmstad, Germany), 1 mmol/l Go¨ 6976
(Ca2þ -dependent PKC inhibitor, Calbiochem), and 10mmol/l PKC-z
pseudosubstrate (Biosource, Nivelles, Belgium). Thereafter, VEGF
was determined in the culture medium. In a second approach,
RGMC were incubated with 100 U/ml IL-1b for 24 h in the absence
or presence of increased concentrations (indicated in the Results
section) of rapamycin, LY 294002, or SB 203580, and the
concentration of VEGF was then determined. To verify if these
pathways were also involved in VEGF expression induced by other
cytokines, RGMC were treated with 20 ng/ml rat recombinant TNFa
(R&D systems Inc., Minneapolis, MN, USA) for 24 h and subjected
to the same studies as IL-1b-treated cells.
Analysis of VEGF in the conditioned medium
VEGF concentration in the culture medium was determined by
enzyme-linked immunosorbent assay (R&D systems) following the
manufacturer’s instructions.
Effect of rapamycin on VEGF levels in the anti-Thy1.1 model
of experimental glomerulonephritis
All animal experiments were conducted in accord with the Animal
Care Committee of the Hospital de la Santa Creu i Sant Pau, and
performed in agreement with the Generalitat de Catalunya guide-
lines for the use of animals in research. Male Wistar rats (Charles
River, Barcelona, Spain) weighing 180–220 g were fed standard rat
chow and tap water ad libitum. Experimental glomerulonephritis
was induced by a single tail vein injection of the monoclonal anti-
Thy1.1 antibody OX-7 (1 mg/1 kg body weight, Cedarlane Labs,
Hornby, Ontario, Canada). The experimental design was similar to
that described previously.57 Briefly, placebo solution or a dose of
3 mg rapamycin/kg body weight/day was administered daily
intraperitoneally from the third day after antibody administration
until the seventh day, when all rats were killed.
Glomeruli were isolated from individual rats as described
previously.27 Glomeruli were immediately lysated and Western
blotting for VEGF evaluation was performed as aforementioned,
using a rabbit polyclonal antibody for VEGF (sc-507, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA); b-actin was detected as
loading control (antibody was from Sigma).
Statistics
Sigma-Stat software was used for statistical analysis. Statistical
significance between pairs of groups was assessed using the Student’s
t-test. A P-value below 0.05 was considered significant.
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